IMRX
HEALTHCAREImmuneering Corp Class A
Live · NASDAQ · May 9, Close
What's Moving IMRX Today?
No stock-specific AI insight has been generated for IMRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.19
Fundamentals
Trading
IMRX News
20 articles- We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash WiselyYahoo Finance·May 6, 2026
- Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and BeyondYahoo Finance·Apr 20, 2026
- Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch NearsMarketbeat·Apr 14, 2026
- Immuneering to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 6, 2026
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and SurvivalYahoo Finance·Mar 17, 2026
- X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention247 Wall St·Mar 9, 2026
- Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 6, 2026
- Immuneering to Present at the Leerink Global Healthcare ConferenceYahoo Finance·Mar 2, 2026
- Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3Marketbeat·Feb 28, 2026
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 18, 2026
- Director of Immuneering Picks Up 1.8% More StockYahoo Finance·Jan 16, 2026
- Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 TransitionYahoo Finance·Jan 11, 2026
- Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's NextYahoo Finance·Jan 10, 2026
- Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3Marketbeat·Jan 8, 2026
- Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPYahoo Finance·Jan 7, 2026
- All You Need to Know About Immuneering (IMRX) Rating Upgrade to BuyYahoo Finance·Dec 29, 2025
- Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026Yahoo Finance·Dec 23, 2025
- Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMAYahoo Finance·Dec 17, 2025
- Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)Yahoo Finance·Dec 16, 2025
All 20 articles loaded
Price Data
52-Week Range
$5.19
Fundamentals
Trading
About Immuneering Corp Class A
Immuneering Corp (IMRX) is an innovative biotechnology company at the forefront of developing advanced therapeutics for cancer and other serious diseases through its proprietary drug discovery platforms. Utilizing cutting-edge bioinformatics and machine learning technologies, Immuneering specializes in identifying and fine-tuning drug candidates that effectively target pivotal biological pathways, aimed at delivering therapies that improve patient outcomes while minimizing toxicity. With a strong pipeline of candidates and strategic partnerships, the company is strategically positioned to lead in the dynamic field of personalized medicine and targeted cancer therapies, offering significant growth potential for investors.